Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Brooks, Colin ^a,c   Sheu, Tommy ^a   Bridges, Kathleen ^a   Mason, Kathy ^a   Kuban, Deborah ^a   Mathew, Paul ^b   Meyn, Raymond ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Combinational therapy; Prostate cancer; Radiation; Sunitinib; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CLONOGENIC ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRROLES; RADIATION-SENSITIZING AGENTS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865968567     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-154     Document Type: Article

References (27)

1. Pisansky TM. External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc 2005, 80(7):883-898. 10.4065/80.7.883, 16007894.
2. Kim DW, Huamani J, Fu A, Hallahan DE. Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy. Init J Radiation Oncology Biol Phys 2006, 64(1):38-46.
3. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, et al. SU5416 and SU6668 Attenuate the Angiogenic Effects of Radiation-induced Tumor Cell Growth Factor Production and Amplify the Direct Anti-endothelial Action of Radiation in Vitro. Cancer Res 2003, 63(13):3755-3763.
4. Wachsberger P, Burd R, Dicker AP. Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interactions. Clin Cancer Res 2003, 9(6):1957-1971.
5. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006, 15(5):553-561. 10.1517/13543784.15.5.553, 16634693.
6. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al. In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors. Clin Cancer Res 2003, 9(1):327-337.
7. de Boüard S, Herlin P, Christensen JG, Lemoisson E, Gauduchon P, Raymond E, Guillamo J-S. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 2007, 9(4):412-423. 10.1215/15228517-2007-024, 1994098, 17622648.
8. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer. Mol Cancer Ther 2003, 2(5):471-478.
9. Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006, 5(5):1280-1289. 10.1158/1535-7163.MCT-03-0156, 16731761.
10. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB. SU11248 (Sunitinib) Sensitizes Pancreatic Cancer to the Cytotoxic Effects of Ionizing Radiation. Int J Radiat Oncol Biol Phys 2008, 71(3):873-879. 10.1016/j.ijrobp.2008.02.062, 18514780.
11. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, McMahon G, Hallahan DE. SU11248 Maintenance Therapy Prevents Tumor Regrowth after Fractionated Irradiation of Murine Tumor Models. Cancer Res 2003, 63(14):4009-4016.
12. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity. Clin Cancer Res 2008, 14(4):1266-1273. 10.1158/1078-0432.CCR-07-1606, 3385646, 18281562.
13. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTINTM; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol 2008, 81(Special Issue 1):S21-S27. 10.1259/bjr/59853976, 18819995.
14. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 2009, 6(5):266-277. 10.1038/nrclinonc.2009.40, 19390553.
15. Sun S, Schiller JH, Spinola M, Minna JD. New molecularly targeted therapies for lung cancer. J Clin Invest 2007, 117(10):2740-2750. 10.1172/JCI31809, 1994616, 17909619.
16. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441(7092):424-430. 10.1038/nature04869, 16724053.
17. De Velasco MA, Uehura H. Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Advances in Urology 2012, 2012:1-12.
18. Rodriguez-Berriguete G, Fraile B, Martinez-Onsurbe P, Olmedilla G, Paniagua R, Royeula M. MAP Kinases and Prostate Cancer. Journal of Signal Transduction 2012, 2012:1-9.
19. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007, 6(3):789-801. 10.1158/1535-7163.MCT-06-0596, 17363476.
20. Jeggo PA, Lobrich M. DNA double-strand breaks: their cellular and clinical impact?. Oncogene 2007, 26(56):7717-7719. 10.1038/sj.onc.1210868, 18066083.
21. Kato TA, Okayasu R, Bedford JS. Comparison of the induction and disappearance of DNA double strand breaks and γ-H2AX foci after irradiation of chromosomes in G1-phase or in condensed metaphase cells. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2008, 639(1-2):108-112.
22. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997, 37(5):1107-1113. 10.1016/S0360-3016(96)00628-1, 9169820.
23. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, Wedge SR. ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy. Clin Cancer Res 2004, 10(24):8587-8593. 10.1158/1078-0432.CCR-04-1147, 15623642.
24. Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler W, Dorfler A, Grenman R, Petersen C, Haberey M, et al. Experimental Study on Different Combination Schedules of VEGF-receptor Inhibitor PTK787/ZK222584 and Fractionated Irradiation. Anticancer Res 2003, 23:3869-3876.
25. Zips D, Hessel F, Krause M, Schiefer Y, Hoinkis C, Thames HD, Haberey M, Baumann M. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005, 61(3):908-914. 10.1016/j.ijrobp.2004.11.007, 15708274.
26. Zips D, Eicheler W, Geyer P, Hessel F, Dörfler A, Thames HD, Haberey M, Baumann M. Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition. Cancer Res 2005, 65(12):5374-5379. 10.1158/0008-5472.CAN-04-3379, 15958586.
27. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Enhancement of radiation response with bevacizumab. J Exp Clin Cancer Res 2012, 31(37). [Epub ahead].